Search for: "LILLI JOHNSON"
Results 121 - 140
of 242
Sorted by Relevance
|
Sort by Date
12 Oct 2015, 1:25 pm
The Chair of the Committee, Alan Johnson (Bristows) emphasized the timeline for in the run-up to the UPC with an anticipated date of mid-2017 for its launch. [read post]
10 Jun 2011, 4:09 pm
Cir. 1997) (hereinafter, Eli Lilly). [read post]
21 Jun 2012, 4:30 am
Johnson & Johnson Corp. v. [read post]
29 Nov 2023, 5:00 am
Challengers soon arrived — Bayer’s Levitra and Eli Lilly’s Cialis broke onto the ED scene in the early 2000s. [read post]
6 Jul 2007, 4:29 am
Johnson & Johnson Corp. v. [read post]
1 Dec 2017, 11:35 am
The evolving treatment regimens are influencing a trend for innovative processes and technological advancement where major pharmaceutical companies are investing in new target-based therapies.[9] Some of the major players setting trends in new drug regimen include Eli Lilly (U.S.), Johnson & Johnson (U.S.), AstraZeneca (U.S), Roche (Switzerland) and Aimmune Therapeutics (U.S.). [read post]
27 Jul 2015, 11:10 am
Ostendorf and making explicit findings on each factor -- Where counsel is involved in conduct to be sanctioned Kozel analysis is required before entering judicial default, and failure to do so is, by itself, basis for remandDOROTHY CHAPPELLE, CALVIN JOHNSON and EVELYN WILLIAMS, Appellants, v. [read post]
12 Aug 2010, 11:56 am
Asencio Azarian, Martin Hunter, Brockton Perry, Jerome Bader, Michael Jakway, Thomas Perry, Shane Baker, Stephen Johnson, … [read post]
9 May 2012, 11:09 am
Johnson & Johnson and Baum v. [read post]
17 Jun 2009, 3:02 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: US: Gene patenting debate continues: UCLA v USPTO (Patent Docs) (Patent Docs) (PatentlyBIOtech) (Patent Docs) (IP Watchdog) US: FTC issues highly anticipated report on follow-on biologics; report concludes that special legislative exclusivity incentives are largely unwarranted for innovators and generics (FDA Law Blog) (Patent Docs) (Patent Docs)… [read post]
1 May 2009, 9:00 am
(IAM) US: Johnson & Johnson – 5 year exclusivity period would kill incentives to innovate (Patent Docs) US: CHI CEO on patent reform and follow-on biologics legislation (Patent Docs) US: BIO urges Congress on patent reform: First, do no harm (Patent Baristas) US: Pharmaceutical advertising: How to use a domain name to circumvent application of law (Domain Name / Nom De Domaine!) [read post]
2 Jun 2010, 8:50 am
Morgan 7 Walt Disney Company 8 Nike 9 Johnson & Johnson 10 Amazon 11 Deloitte 12 The Blackstone Group 13 Morgan Stanley 14 Microsoft 15 General Electric 16 Procter & Gamble 17 IDEO 18 The Coca-Cola Co. 19 Credit Suisse 20 Barclays Capital 21 American Express 22 PepsiCo 23 Starbucks 24 Bank of America 25 Sony 26 BMW 27 LVMH 28 Nestlé USA 29 IBM 30 Booz & Company 31 Starwood Hotels & Resorts 32 3M 33 Deutsche Bank 34 Unilever 35 Genentech 36 Intel 37 General… [read post]
17 Jun 2009, 3:02 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: US: Gene patenting debate continues: UCLA v USPTO (Patent Docs) (Patent Docs) (PatentlyBIOtech) (Patent Docs) (IP Watchdog) US: FTC issues highly anticipated report on follow-on biologics; report concludes that special legislative exclusivity incentives are largely unwarranted for innovators and generics (FDA Law Blog) (Patent Docs) (Patent… [read post]
13 Jun 2011, 7:54 am
., Eli Lilly & Co., Johnson & Johnson, and Pfizer Inc. were among the companies that supported Roche. [read post]
23 Mar 2007, 11:35 am
., Beckman Coulter, Bridgestone Americas, Bristol-Myers Squibb, Cargill Incorporated, Caterpillar, Cephalon, CheckFree, Corning, Dow Chemical, Eastman Chemical, Electronics for Imaging, E.I. du Pont (DuPont), Eli Lilly, ExxonMobil, General Electric, Genzyme, GlaxoSmithKline, Henkel Corporation, Hoffman-La Roche, Johnson & Johnson, Merck, Millennium Pharmaceuticals, Monsanto, Motorola, Novartis, Patent Café.com Inc., Pfizer, Procter… [read post]
6 Sep 2012, 9:17 am
WuXi is responsible for manufacturing hepatitis C therapy INCIVEK® for Vertex and Johnson & Johnson (www.jnj.com); the drug's first full quarter of sales since launch was a driver behind this huge jump in manufacturing services revenue compared to the prior year. [read post]
15 Oct 2008, 8:38 am
AAJ obtained emails that list attendees of a meeting between Bradshaw and the Pharmaceutical Research and Manufacturers of America (PhRMA) revealing the FDA chief counsel met with legal representatives from Pfizer, Wyeth, Eli Lilly, Berlex, Organon, Abbott Laboratories, Takeda, Sanofi-Aventis, Serono, AstraZeneca, Cephalon, Millenium, Eisai, Amgen, Astellas, GlaxoSmithKline, Bristol Myers Squibb, Johnson & Johnson, Novartis, Merck, and 3M.Less than six months after… [read post]
8 Mar 2012, 3:34 am
Eli Lilly & Co. [read post]
10 Jan 2012, 11:58 pm
Johnson & Johnson, 647 F.3d 1353, 1366 (Fed. [read post]
5 Mar 2024, 10:55 am
Since 2019, the following pharmaceutical manufacturers have posted seven or more notices of correction: Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck & Co., Novo Nordisk, and Purdue Pharmaceuticals. [read post]
